Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 first-line trial of ibrutinib + venetoclax versus obinutuzumab + chlorambucil in CLL/SLL
MOH_2018-03-21_002273Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2018
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ibrutinib, venetoclax, obinutuzumab and chlorambucil in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival. Started Feb 2018; status: active, not recruiting.
02
Drugs
ibrutinibvenetoclaxobinutuzumabchlorambucil
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on MOH_2018-03-21_002273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-03-21_002273.